CRSP CRISPR Therapeutics AG - Common Shares
$56.87
Price · Aug 19, 2026
Fundamentals as of Aug 3, 2026
52W Range
$44–$78
37% of range
Analyst Rating
HOLD
29 analysts
Price Target
$88
+54% upside
P/E (TTM)
-8.8
ROE
-32.0%
Net Profit Margin
-16569.8%
About CRISPR Therapeutics AG - Common Shares Company overview from Wikipedia
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
Read more
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
CRSP Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$56.87
Market Cap
$5.45B
P/E (TTM)
-8.8
EPS (TTM)
$-6.47
Revenue (TTM)
$4M
Div Yield
—
ROE
-32.0%
Debt/Equity
—
52W Range
$44 – $78
CRSP Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
$4M
2016-12-31
→
2025-12-31
EPS
$-6.47
2017-12-31
→
2025-12-31
Free Cash Flow
$-346M
2016-12-31
→
2025-12-31
Margins
-16569.8%
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
CRSP
Peer Median
P/E (TTM)
-8.8
—
P/S (TTM)
1553.7
56.3
P/B
2.8
3.0
Price / FCF
-15.8
—
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
CRSP
Peer Median
Operating Margin
-18933.7%
—
Net Profit Margin
-16569.8%
-1643.9%
ROA
-25.8%
-40.2%
ROE
-32.0%
-75.3%
ROIC
-34.8%
—
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
CRSP
Peer Median
Current Ratio
13.3
6.7
Quick Ratio
13.2
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
CRSP
Peer Median
Revenue YoY
-90.6%
—
Revenue CAGR 3Y
43.1%
—
Revenue CAGR 5Y
37.3%
—
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
CRSP
Peer Median
CRSP Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
29 analysts
- Strong Buy 6 20.7%
- Buy 11 37.9%
- Hold 12 41.4%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
18 analysts · 2026-08-15
Median
$80.00
Now
$56.87
Low
$44.00
High
$291.00
Median target
$80.00
+40.7%
Mean target
$87.56
+54.0%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.01%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-0.94 | $-1.22 | 0.28% |
| March 31, 2026 | $-1.28 | $-1.25 | -0.03% |
| Dec. 31, 2025 | $-1.37 | $-1.18 | -0.19% |
| Sept. 30, 2025 | $-1.17 | $-1.29 | 0.12% |
| June 30, 2025 | $-1.29 | $-1.45 | 0.16% |
| March 31, 2025 | $-1.58 | $-1.28 | -0.30% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| CRSP | $5.03B | -8.1 | -90.6% | -16569.8% | -32.0% | — |
| MLTX | — | -3.7 | — | — | -60.5% | — |
| ACIU | — | — | — | — | — | — |
| ADCT | $444M | -3.2 | 14.8% | -175.3% | 74.1% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 15
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
Balance Sheet 25
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
Cash Flow 14
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
Profitability 7
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
Liquidity & Solvency 2
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
Efficiency 2
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
Growth Rates 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM) 10
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
Income Statement 14
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
Balance Sheet 25
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
Cash Flow 11
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
Profitability 7
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
Liquidity & Solvency 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
Efficiency 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
Valuation (TTM) 10
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $3M | $3M | $2M | · | $2M | $71M | $171M | · | $170M | $170M | $101M | · | $2M | |
| Net Income TTM | $-529M | $-574M | · | $-537M | $-557M | $-465M | · | $-441M | $-433M | $-360M | · | $-418M | $-491M | $-593M | · | $-667M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -9.4 | -7.4 | · | -10.5 | -7.5 | -6.2 | · | -8.8 | -10.2 | -15.2 | · | -8.6 | -8.9 | -5.9 | · | -7.6 | |
| P/S | 392.8 | 1117.2 | · | 1873.1 | 1494.7 | 1181.2 | · | 2470.2 | 64.7 | 33.9 | · | 21.2 | 26.2 | 35.2 | · | 2536.5 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| P / FCF | · | -41.9 | · | · | · | -54.3 | · | · | · | 53.0 | · | · | · | 621.4 | · | · | |
| Earnings Yield | -10.6% | -13.5% | · | -9.5% | -13.3% | -16.2% | · | -11.4% | -9.8% | -6.6% | · | -11.7% | -11.2% | -16.9% | · | -13.2% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M |
| Operating Margin % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M |
| Diluted EPS | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
Cash Flow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M |
Latest News Recent headlines mentioning this company
- Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
- 2 Beaten-Down Stocks With Massive Upside Potential
- CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
- CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
- Mega-Cap Growth Leadership or Small-Cap Growth Potential? VUG vs. VBK
- 1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
- Notable ETF Outflow Detected - ARKK, CRSP, TEM, HOOD
- This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area
- Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
- Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position?
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 573 filers · $3.3B total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 89 (0 vs prior Q) | 47 (-13 vs prior Q) | 148 (-24 vs prior Q) | 145 (+21 vs prior Q) | +5.4M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| ARK Investment Management LLC | $515,999,631 | 9,460,939 | 15.58% | Shares |
| Orbis Allan Gray Ltd | $296,334,582 | 5,433,344 | 8.95% | Shares |
| Capital World Investors | $259,039,094 | 4,749,525 | 7.82% | Shares |
| STATE STREET CORP | $235,703,664 | 4,321,666 | 7.12% | Shares |
| GSK plc | $175,652,997 | 3,220,627 | 5.30% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $117,453,717 | 2,153,015 | 3.55% | Shares |
| SR One Capital Management, LP | $111,194,134 | 2,038,763 | 3.36% | Shares |
| TWO SIGMA INVESTMENTS, LP | $108,459,389 | 1,988,621 | 3.27% | Shares |
| Sumitomo Mitsui Trust Group, Inc. | $93,848,832 | 1,720,734 | 2.83% | Shares |
| Amova Asset Management Americas, Inc. | $93,762,487 | 1,720,097 | 2.83% | Shares |
| EcoR1 Capital, LLC | $75,771,113 | 1,389,276 | 2.29% | Shares |
| Capital International Investors | $69,178,918 | 1,268,407 | 2.09% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $64,457,935 | 1,181,847 | 1.95% | Shares |
| NEA Management Company, LLC | $57,734,408 | 1,058,570 | 1.74% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57,694,430 | 1,057,837 | 1.74% | Shares |
| FMR LLC | $53,577,751 | 982,357 | 1.62% | Shares |
| D. E. Shaw & Co., Inc. | $48,748,506 | 893,812 | 1.47% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35,380,807 | 648,713 | 1.07% | Shares |
| UBS Group AG | $32,419,612 | 594,419 | 0.98% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $31,089,982 | 570,040 | 0.94% | Shares |
| VANGUARD GROUP INC | $27,714,225 | 528,494 | 0.84% | Shares |
| CITADEL ADVISORS LLC | $25,404,514 | 465,796 | 0.77% | Shares |
| BANK OF AMERICA CORP /DE/ | $23,509,740 | 431,055 | 0.71% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23,298,288 | 427,178 | 0.70% | Shares |
| MILLENNIUM MANAGEMENT LLC | $20,836,025 | 382,032 | 0.63% | Shares |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20,833,789 | 381,991 | 0.63% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18,456,336 | 338,400 | 0.56% | Put option |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17,763,678 | 325,700 | 0.54% | Call option |
| Logos Global Management LP | $16,362,000 | 300,000 | 0.49% | Shares |
| CITADEL ADVISORS LLC | $15,822,054 | 290,100 | 0.48% | Put option |
| Squarepoint Ops LLC | $15,641,472 | 286,789 | 0.47% | Shares |
| NORGES BANK | $14,767,032 | 270,756 | 0.45% | Shares |
| CITADEL ADVISORS LLC | $13,973,148 | 256,200 | 0.42% | Call option |
| GOLDMAN SACHS GROUP INC | $12,748,193 | 233,740 | 0.38% | Shares |
| JANE STREET GROUP, LLC | $12,566,016 | 230,400 | 0.38% | Call option |
| PEAK6 LLC | $11,633,382 | 213,300 | 0.35% | Put option |
| Swiss National Bank | $9,228,168 | 169,200 | 0.28% | Shares |
| Susquehanna Portfolio Strategies, LLC | $8,945,978 | 164,026 | 0.27% | Shares |
| TWO SIGMA ADVISERS, LP | $8,516,256 | 162,400 | 0.26% | Shares |
| LPL Financial LLC | $8,376,280 | 153,581 | 0.25% | Shares |
| Bank of New York Mellon Corp | $8,337,366 | 152,867 | 0.25% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $8,301,261 | 152,205 | 0.25% | Shares |
| Versant Venture Management, LLC | $8,117,243 | 148,831 | 0.25% | Shares |
| Pictet Asset Management Holding SA | $7,989,776 | 142,213 | 0.24% | Shares |
| Life Cycle Investment Partners Ltd | $7,836,962 | 143,692 | 0.24% | Shares |
| TD Asset Management Inc | $7,777,513 | 142,602 | 0.23% | Shares |
| AMERICAN CENTURY COMPANIES INC | $7,606,257 | 139,462 | 0.23% | Shares |
| RAYMOND JAMES FINANCIAL INC | $7,230,750 | 132,577 | 0.22% | Shares |
| RHUMBLINE ADVISERS | $6,627,197 | 121,511 | 0.20% | Shares |
| SFE Investment Counsel | $6,229,434 | 16,700 | 0.19% | Put option |
| Private Advisor Group, LLC | $6,060,980 | 111,129 | 0.18% | Shares |
| EverSource Wealth Advisors, LLC | $6,032,669 | 110,610 | 0.18% | Shares |
| CONGRESS ASSET MANAGEMENT CO | $5,969,567 | 109,453 | 0.18% | Shares |
| BlackRock, Inc. | $5,937,061 | 108,857 | 0.18% | Shares |
| D. E. Shaw & Co., Inc. | $5,901,228 | 108,200 | 0.18% | Call option |
| Campbell & CO Investment Adviser LLC | $5,864,632 | 107,529 | 0.18% | Shares |
| JANE STREET GROUP, LLC | $5,852,142 | 107,300 | 0.18% | Put option |
| California Public Employees Retirement System | $5,599,567 | 102,669 | 0.17% | Shares |
| CAPITAL INTERNATIONAL SARL | $5,521,521 | 101,238 | 0.17% | Shares |
| Affinity Asset Advisors, LLC | $5,454,000 | 100,000 | 0.16% | Shares |
| ALLIANCEBERNSTEIN L.P. | $5,439,011 | 114,337 | 0.16% | Shares |
| CLOUGH CAPITAL PARTNERS L P | $5,363,300 | 98,337 | 0.16% | Shares |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $5,172,465 | 94,838 | 0.16% | Shares |
| Slow Capital, Inc. | $5,066,439 | 92,894 | 0.15% | Shares |
| CAPITAL FUND MANAGEMENT S.A. | $4,867,258 | 89,242 | 0.15% | Shares |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $4,815,606 | 101,232 | 0.15% | Shares |
| VANGUARD ASSET MANAGEMENT, Ltd | $4,720,437 | 86,550 | 0.14% | Shares |
| GROUP ONE TRADING LLC | $4,638,082 | 85,040 | 0.14% | Shares |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | $4,575,742 | 83,897 | 0.14% | Shares |
| STATE OF MICHIGAN RETIREMENT SYSTEM | $4,502,113 | 82,547 | 0.14% | Shares |
| Concurrent Investment Advisors, LLC | $4,497,728 | 82,467 | 0.14% | Shares |
| WELLS FARGO & COMPANY/MN | $4,309,151 | 79,009 | 0.13% | Shares |
| Fisher Asset Management, LLC | $4,251,957 | 77,960 | 0.13% | Shares |
| Trexquant Investment LP | $4,225,268 | 77,471 | 0.13% | Shares |
| COMMONWEALTH EQUITY SERVICES, LLC | $4,194,122 | 76,900 | 0.13% | Shares |
| JONES FINANCIAL COMPANIES LLLP | $4,055,652 | 73,847 | 0.12% | Shares |
| Man Group plc | $3,992,001 | 73,194 | 0.12% | Shares |
| PEAK6 LLC | $3,834,162 | 70,300 | 0.12% | Call option |
| ENVESTNET ASSET MANAGEMENT INC | $3,822,196 | 70,081 | 0.12% | Shares |
| ALGERT GLOBAL LLC | $3,593,095 | 65,880 | 0.11% | Shares |
| Walleye Trading LLC | $3,528,738 | 64,700 | 0.11% | Put option |
| MILLENNIUM MANAGEMENT LLC | $3,146,958 | 57,700 | 0.10% | Call option |
| CAPITAL INTERNATIONAL LTD /CA/ | $3,057,840 | 56,066 | 0.09% | Shares |
| NOMURA HOLDINGS INC | $3,055,713 | 56,027 | 0.09% | Shares |
| Rafferty Asset Management, LLC | $3,045,132 | 55,833 | 0.09% | Shares |
| Green Alpha Advisors, LLC | $3,043,550 | 55,804 | 0.09% | Shares |
| Walleye Trading LLC | $3,005,154 | 55,100 | 0.09% | Call option |
| Caption Management, LLC | $2,999,700 | 55,000 | 0.09% | Call option |
| MetLife Investment Management, LLC | $2,958,413 | 54,243 | 0.09% | Shares |
| BENJAMIN EDWARDS INC | $2,956,845 | 54,216 | 0.09% | Shares |
| Quantinno Capital Management LP | $2,869,349 | 52,610 | 0.09% | Shares |
| Cetera Investment Advisers | $2,856,133 | 52,368 | 0.09% | Shares |
| STATE OF WISCONSIN INVESTMENT BOARD | $2,788,521 | 51,128 | 0.08% | Shares |
| CITIGROUP INC | $2,781,540 | 51,000 | 0.08% | Call option |
| CITIGROUP INC | $2,781,540 | 51,000 | 0.08% | Put option |
| WOLVERINE ASSET MANAGEMENT LLC | $2,727,000 | 50,000 | 0.08% | Put option |
| OSAIC HOLDINGS, INC. | $2,693,150 | 49,381 | 0.08% | Shares |
| Privium Fund Management B.V. | $2,452,882 | 44,974 | 0.07% | Shares |
| CANADA PENSION PLAN INVESTMENT BOARD | $2,394,306 | 43,900 | 0.07% | Shares |
| TUDOR INVESTMENT CORP ET AL | $2,318,604 | 42,512 | 0.07% | Shares |
Company insiders 32 insiders · 12 officers · 16 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | March 20, 2026 M | 255,501 | 0 | 9 | $-10,756,932 |
| Brendan Smith | Chief Financial Officer | Feb. 18, 2023 M | 5,072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | March 11, 2021 M | 1,891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | March 20, 2025 M | 10,544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | Aug. 16, 2022 A | 26,797 | 0 | 0 | $0 |
| Naimish Patel | Chief Medical Officer | May 29, 2026 A | 19,357 | 1 | 2 | $-312,892 |
| James R. Kasinger | General Counsel and Secretary | May 29, 2026 A | 94,308 | 0 | 5 | $-645,902 |
| Phuong Khanh Morrow | Chief Medical Officer | Oct. 13, 2023 A | 4,411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | Dec. 3, 2021 M | 52,364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | Jan. 16, 2018 M | 25,204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | June 15, 2017 A | — | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | Oct. 24, 2016 C | 505,617 | 0 | 0 | $0 |
| Christian Rommel | Director | June 5, 2026 A | — | 0 | 0 | $0 |
| Harold Edward Fleming | Director | June 5, 2026 A | — | 0 | 0 | $0 |
| Douglas A Treco | Director | June 5, 2026 A | — | 0 | 0 | $0 |
| Briggs Morrison | Director | June 5, 2026 A | — | 0 | 0 | $0 |
| Katherine A High | Director | June 5, 2026 A | — | 0 | 0 | $0 |
| Ali Behbahani | Director | June 5, 2026 A | 14 | 0 | 0 | $0 |
| John Greene | Director | June 5, 2026 A | 7,000 | 0 | 0 | $0 |
| Simeon George | Director | June 5, 2026 A | 1,730,179 | 0 | 0 | $0 |
| Maria Fardis | Director | June 5, 2026 A | — | 0 | 0 | $0 |
| Sandesh Mahatme | Director | June 5, 2026 A | — | 0 | 0 | $0 |
| Bradley J Bolzon PhD | Director | June 9, 2022 A | 148,831 | 0 | 0 | $0 |
| Pablo J Cagnoni | Director | Nov. 19, 2019 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | Director | Dec. 18, 2018 S | 1,171,268 | 0 | 0 | $0 |
| Thomas Woiwode | Director | June 15, 2018 A | 640,014 | 0 | 0 | $0 |
| Anthony N Coles | Director | May 31, 2017 A | 70,000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | 10% owner | Dec. 4, 2017 S | 3,722,534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | 10% owner | Oct. 24, 2016 C | 744,380 | 0 | 0 | $0 |
| GSK plc | 10% owner | Oct. 24, 2016 C | 3,220,627 | 0 | 0 | $0 |
| Raju Prasad | — | Aug. 7, 2026 G | 14,815 | 0 | 10 | $-5,100,841 |
| Rodger Novak | — | June 30, 2021 S | 573,007 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 6 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 filings | Feb. 16, 2021 | — | Initial filing | — | SEC |
| GlaxoSmithKline plc ×5 filings | July 10, 2020 | — | Initial filing | — | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 filings | Feb. 4, 2020 | — | Initial filing | — | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 filings | June 7, 2019 | — | Initial filing | — | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 filings | Feb. 8, 2018 | — | Initial filing | — | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 filings | Jan. 16, 2018 | — | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 32 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| GNOM · Global X Funds | 3.85% | 38,191 NS | May 31, 2026 | N-PORT |
| IDNA · iShares Trust | 1.63% | 62,247 SH | Aug. 8, 2026 | Daily |
| LABU · Direxion Shares ETF Trust | 0.98% | 97,235 NS | April 30, 2026 | N-PORT |
| IBB · iShares Trust | 0.36% | 658,537 SH | Aug. 8, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.35% | 5,248 SH | Aug. 8, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.28% | 70,696 SH | Aug. 8, 2026 | Daily |
| IWN · iShares Trust | 0.27% | 752,223 SH | Aug. 8, 2026 | Daily |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.21% | 104,016 NS | May 31, 2026 | N-PORT |
| ISCV · iShares Trust | 0.15% | 20,568 SH | Aug. 8, 2026 | Daily |
| IWM · iShares Trust | 0.15% | 2,353,025 SH | Aug. 8, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.15% | 536,446 SH | Aug. 8, 2026 | Daily |
| RSSL · Global X Funds | 0.15% | 39,589 NS | April 30, 2026 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trust … | 0.10% | 6,636 SH | Aug. 8, 2026 | Daily |
| ISCB · iShares Trust | 0.07% | 4,136 SH | Aug. 8, 2026 | Daily |
| SMLF · iShares Trust | 0.07% | 57,970 SH | Aug. 8, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.06% | 1,106,455 SH | Aug. 8, 2026 | Daily |
| ESML · iShares Trust | 0.06% | 33,283 SH | Aug. 8, 2026 | Daily |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.06% | 108 NS | May 31, 2026 | N-PORT |
| WSML · iShares Trust | 0.04% | 5,486 SH | Aug. 8, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 13,170 SH | Aug. 8, 2026 | Daily |
| IWO · iShares Trust | 0.04% | 109,974 SH | Aug. 8, 2026 | Daily |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.03% | 1,736 SH | Aug. 8, 2026 | Daily |
| XT · iShares Trust | 0.03% | 21,837 SH | Aug. 8, 2026 | Daily |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.03% | 3,509 NS | May 31, 2026 | N-PORT |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.01% | 7,774 SH | Aug. 8, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.01% | 20,627 SH | Aug. 8, 2026 | Daily |
| IYY · iShares Trust | 0.01% | 4,231 SH | Aug. 8, 2026 | Daily |
| ITOT · iShares Trust | 0.01% | 128,511 SH | Aug. 8, 2026 | Daily |
| AVUS · AMERICAN CENTURY ETF TRUST | 0.01% | 15,609 NS | May 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.01% | 25,457 SH | Aug. 8, 2026 | Daily |
| AVSU · AMERICAN CENTURY ETF TRUST | 0.00% | 289 NS | May 31, 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.00% | 75,392 SH | Aug. 8, 2026 | Daily |